Press Releases<< Back
CareDx and Allegheny General Hospital Launch Research Study of Novel Test to Screen Heart Transplant Recipients for Signs of Rejection
This study, known as Donor-derived cell-free DNA Outcomes AlloMap Registry (D-OAR), will examine the heart transplant patient's blood for circulating DNA from the donor to determine whether the presence of this biomarker can assist in diagnosing rejection. The study is based on the premise that donor derived cell-free DNA is released from the heart cells in response to injury from rejection.
The D-OAR trial is a sub-study of the long-term Outcomes AlloMap Registry (OAR), a multi-center, multi-year outcomes study correlating serial AlloMap® scores with cardiac dysfunction and biopsy proven rejection in heart transplant recipients. The AlloMap test has been shown to aid physicians in determining a transplant patient's risk of acute cellular rejection without requiring the use of invasive endomyocardial biopsy.
"This is the first time that clinicians will prospectively observe in patients cell-free DNA research test results together with commercially available AlloMap scores," said
"Circulating donor-derived DNA in the blood may serve as an important biomarker for immune surveillance and significantly improve the way we diagnose rejection in heart transplant patients," said
Allegheny General is one of three initial transplant centers in
One of the leading enrollment centers in the U.S. for the OAR trial, AGH has 34 patients in the AlloMap registry and has already enrolled eight patients in the D-OAR sub-study.
"Better, reliable, non-invasive solutions are needed to diagnose rejection in heart transplant patients," said
There are approximately 2,000 new heart transplants recipients annually in
AlloMap Molecular Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the
Forward Looking Statements
This press release contains forward-looking statements including, but not limited to, statements regarding the conduct, results and impact of the D-OAR study, the development of a cell-free DNA based test for heart transplant rejection and the impact of such a test on patient care and patient outcomes. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements including
CareDx, Inc. Bradley P. SherrillSenior Director, Marketing Tel: 415-287-2397 bsherrill@CareDxInc.com Allegheny Health Network Jennifer DavisMedia Communications Specialist Tel: 412-330-4439 email@example.com
News Provided by Acquire Media